Table 2—

Sensitivity, specificity, and predicted values of IGT and the metabolic syndrome for identifying subjects at risk for type 2 diabetes

SensitivitySpecificityPositive predictive valueNegative predictive value
IGT (2-h glucose ≥7.8 mmol/l in nondiabetic subjects)51.991.543.093.9
IFG (fasting glucose ≥6.1 mmol/l in nondiabetic subjects)9.298.951.489.6
NCEP definition52.884.930.893.4
Modified WHO definition42.887.230.492.1
NCEP definition and/or IGT70.879.129.795.6
Modified WHO definition and/or IGT66.380.930.794.9
Fasting plasma glucose requirement changed to ≥5.4 mmol/l
 Fasting glucose ≥5.4 mmol/l42.691.739.392.6
 NCEP definition with fasting glucose ≥5.4 mmol/l*62.082.430.994.5
 Modified WHO definition with fasting glucose ≥5.4 mmol/l49.585.430.692.9
 NCEP definition and/or a fasting glucose ≥5.4 mmol/l69.779.029.795.3
 Modified WHO definition and/or a fasting glucose ≥5.4 mmol/l60.381.129.394.0
  • * The NCEP definition with fasting glucose ≥5.4 mmol/l required at least three of the following: increased waist circumference (>102 cm in men and >88 cm in women), high triglycerides (≥1.7 mmol/l), low HDL cholesterol (<1.04 mmol/l in men and <1.29 mmol/l in women), high blood pressure (≥130/85 mmHg or treated for hypertension), and fasting plasma glucose (≥5.4 mmol/l);

  • modified WHO definition with fasting glucose ≥5.4 mmol/l required fasting plasma glucose ≥5.4 mmol/l or hyperinsulinemia (fasting insulin in the top quartile of the nondiabetic population) plus at least two of the following: obesity (BMI ≥30 kg/m2 or waist-to-hip ratio >0.9 in men and >0.85 in women), dyslipidemia (HDL cholesterol <0.9 mmol/l in men and <1.0 mmol/l in women or triglycerides ≥1.7 mmol/l), and hypertension (≥140/90 mmHg or treated for hypertension).